Table 1 Patient characteristics before and after propensity score matching.

From: Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment

Patient number 187

Before matching

After matching

Etanercept (81)

Tocilizumab (106)

p-value

Etanercept (38)

Tocilizumab (38)

p-value

Sex female/ male

65/ 16

81/ 25

0.328

12/26

14/ 24

0.809

Age

51.3 ± 13.7

62.8 ± 12.5

 < 0.001

57.0 ± 13.1

56.0 ± 12.4

0.741

RA duration

3.6 ± 3.7

8.6 ± 9.2

 < 0.001

4.2 ± 4.3

4.7 ± 6.7

0.684

First bDMARDs

64

53

 

26

23

 

Second or more bDMARDs

17

53

 < 0.001

12

15

0.632

CDAI

20.3 ± 12.6

22.9 ± 13.1

0.210

22.3 ± 12.9

18.3 ± 9.7

0.127

mHAQ

0.6 ± 0.7

0.6 ± 0.6

0.731

0.7 ± 0.8

0.6 ± 0.5

0.172

CRP

1.9 ± 2.2

2.8 ± 2.6

0.024

2.5 ± 2.5

2.2 ± 2.1

0.606

MMP3

240 ± 257

277 ± 202

0.300

329 ± 327

289 ± 224

0.529

MTX dose (mg/week)

3.9 ± 5.1

3.9 ± 4.2

0.958

3.7 ± 4.0

3.3 ± 4.3

0.310

Glucocorticoid dose (mg/day)

2.0 ± 2.6

2.6 ± 2.8

0.133

2.9 ± 2.9

2.4 ± 2.4

0.356

Total Sharp score

20.5 ± 32.5

17.8 ± 52.1

0.701

26.1 ± 40.1

27.6 ± 74.0

0.913

  1. bDMARDs biological disease-modifying antirheumatic drugs, CRP C-reactive protein, MMP-3 matrix metalloproteinase-3, CDAI clinical disease activity index (CDAI), mHAQ modified health assessment questionnaire, MTX methotrexate.
Back to article page